Seyed Jafari, S Morteza; Folini-Huesser, Flavia; Cazzaniga, Simone; Hunger, Robert E (2023). Long-Term Follow-Up of Lentigo Maligna Patients Treated with Imiquimod 5% Cream. Cancers, 15(5) MDPI AG 10.3390/cancers15051546
|
Text
cancers-15-01546-v2.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview |
BACKGROUND
The study investigated the long-term efficacy of imiquimod 5% cream for LM, with a focus on disease recurrence and the possible prognostic factors of disease-free survival (DFS) in a cohort, with long-term follow-up.
METHODS
Consecutive patients with histologically confirmed LM were included. Imiquimod 5% cream was applied until weeping erosion appeared on the LM-affected skin. The evaluation was performed through clinical examination and dermoscopy.
RESULTS
We analyzed 111 patients with LM (median age: 72 years, 61.3% women) with tumor clearance after imiquimod therapy, with a median follow-up of 8 years. The overall patient survival rates were 85.5% (95% confidence interval (CI): 78.5-92.6) and 70.4% (95% CI: 60.3-80.5) at 5 and 10 years, respectively. Among the 23 patients (20.1%) with relapse at follow-up, 17 (73.9%) were treated with surgery, five (21.7%) continued imiquimod therapy, and one (4.3%) underwent both surgery and radiotherapy. After adjustment for age and LM area in multivariable models, localization of LM in the nasal region was identified as a prognostic factor for DFS (HR = 2.66; 95% CI: 1.06-6.64).
CONCLUSION
If surgical excision is not possible due to the patients' age/comorbidities or critical cosmetic localization, imiquimod could provide optimal outcomes with an optimal risk of relapse for the management of LM.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Pathologie > Forschungsgruppe Dermatologie |
UniBE Contributor: |
Jafari, Morteza, Cazzaniga, Simone, Hunger, Robert |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2072-6694 |
Publisher: |
MDPI AG |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
12 Mar 2023 13:35 |
Last Modified: |
14 Mar 2023 02:12 |
Publisher DOI: |
10.3390/cancers15051546 |
PubMed ID: |
36900337 |
Uncontrolled Keywords: |
imiquimod therapy lentigo maligna non-invasive therapy |
BORIS DOI: |
10.48350/179920 |
URI: |
https://boris.unibe.ch/id/eprint/179920 |
Actions (login required)
 |
Edit item |